906 followers
New article: Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2- Advanced or Metastatic Breast Cancer: A US Payer Perspective https://t.co/Gb7nLil8ak #breastcancer #oncology https://t.co/Ovg9YGMC